^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BRCA2 mutation + TP53 mutation

i
Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
1m
BRCA2 and TP53 Mutations in a Breast Cancer Patient: A Case Report and Review of the Literature. (PubMed, Cureus)
Multigene tests are essential in the treatment approach to young BC patients, since the detection of specific mutations may help guide changes in preventive measures and treatment plans. This report describes a rare case of BC in a young patient with pathogenic germline variants in BRCA2 and TP53 genes and also presents a literature review of the topic.
Review • Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2)
|
TP53 mutation • BRCA2 mutation + TP53 mutation
8ms
Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing. (PubMed, Eur J Med Res)
This comprehensive analysis of somatic mutations in HGSOC provides insight into potential therapeutic targets and molecular pathways for targeted interventions. AP3S1 was identified as being a key player in tumor immunity and prognosis, thus providing new perspectives for personalized treatment strategies. The findings of this study contribute to the understanding of HGSOC pathogenesis and provide a foundation for improved outcomes in patients with this aggressive disease.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TGFB1 (Transforming Growth Factor Beta 1)
|
TP53 mutation • BRCA1 mutation • BRCA2 mutation + TP53 mutation
over2years
Myxoid mesenchymal lesions (ECP 2022)
with myxoid background stroma, including variably sized pools of basophilic material, or collagenous with frequent collagen plaques, they display spindled cells with scant to relatively abundant gray to eosinophilic cytoplasm and spindled to ovoid or much less commonly round nuclei with inconspicuous nucleoli and evenly distributed chromatin without overt pleomorphism and show strong and diffuse CyclinD1 positivity with BCOR being positive in ~ 50% of cases with CD10 positive and ER/PR +/- and the caveat of focal positivity for SMA and caldesmon in some. • Caution should be exercised when evaluating a myxoid smooth muscle tumor and extensive sampling is crucial including sections of the tumor myometrium interface to evaluate margins and detect any area with cytologic atypia or increased mitotic activity as not infrequently these tumors may have banal cytologic features • To establish a diagnosis of myxoid leiomyoma, the tumor should be <6 cm, well circumscribed, with no cytologic atypia or mitotic activity • In the frozen section setting, a tumor that has grown fast and surgeon suspects leiomyosarcoma, the most common diagnosis will be leiomyoma with hydropic change • When a lymphoplasmacytic inflammatory infiltrate is noted within a spindled cell proliferation that resembles a smooth muscle neoplasm especially with a myxoid component, think of the possibility of an inflammatory myofibroblastic tumor • Caution should be exercised when using smooth muscle markers including transgelin, and endometrial stromal markers including CD10, IFITM1, and BCOR in the differential diagnosis with these tumors • When working up such differential diagnosis apply smooth muscle markers as well as ALK/ROS and perform FISH • In a malignant myxoid spindle cell tumor negative for BCOR and muscle markers showing diffuse cyclinD1 expression perform molecular studies to rule out a BCOR high-grade endometrial stromal sarcoma
Tumor Mutational Burden • BRCA Biomarker
|
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CCND1 (Cyclin D1) • BCOR (BCL6 Corepressor) • MME (Membrane Metalloendopeptidase) • NTRK (Neurotrophic receptor tyrosine kinase) • PLAG1 (PLAG1 Zinc Finger) • TAGLN (Transgelin)
|
TP53 mutation • BRCA2 mutation • ALK positive • ROS1 positive • ER positive + PGR positive • CCND1 expression • BRCA2 mutation + TP53 mutation
over2years
Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study. (PubMed, Cancers (Basel))
A cribriform pattern/intraductal carcinoma might be a marker of potentially lethal PC. The high incidence of TP53 and BRCA2 mutations in de novo mCSPC may also have a therapeutic implication.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset)
|
TP53 mutation • BRCA2 mutation • BRCA2 mutation + TP53 mutation